Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies

Anticoagulant therapy is a major component in the management of acute coronary syndromes (ACS). Four anticoagulant agents are currently commercially available for ACS, namely unfractionated heparin (UFH), enoxaparin, bivalirudin and fondaparinux. We describe the advantages of fondaparinux and the re...

Descripción completa

Detalles Bibliográficos
Autor principal: Schiele, François
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856573/
https://www.ncbi.nlm.nih.gov/pubmed/20407625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856573/
https://www.ncbi.nlm.nih.gov/pubmed/20407625

Ejemplares similares